Purpose. Respiratory tract infections are a major cause of global morbidity and mortality. Pneumonia is the ninth leading cause of mortality in Sri Lanka. Atypical pathogens cause about one-fifth of community-acquired pneumonia, while Mycoplasma pneumoniae accounts for about 50 %. This study aimed to determine the seroprevalence of M. pneumoniae respiratory tract infections in Sri Lanka while attempting to understand the relationships between the serology and PCR.
INTRODUCTION
Respiratory tract infections are a major cause of mortality and morbidity. Lower respiratory tract infections have become the third leading cause of death worldwide [1] . Pneumonia is the most severe of these infections. The World Health Organization reported that pneumonia accounts for 16 % of all paediatric deaths under 5 years of age, with 920 136 deaths in 2015 [2] . The highest rates of pneumonia are reported in developing nations, particularly in South Asia and sub-Saharan Africa [2] . In Sri Lanka, as per 2015 figures, pneumonia was the seventh leading cause of hospital mortality [3] .
Pneumonia is caused by a range of micro-organisms. Streptococcus pneumoniae, which is readily recovered in the laboratory, is the predominant cause of typical pneumonia. However, one-fifth of community-acquired pneumonia cases are atypical. The pleuro-pneumonia-like organism (PPLO), Mycoplasma pneumoniae, is the commonest causative agent of primary atypical pneumonia, accounting for >50 % of paediatric community-acquired pneumonia (CAP) and 32.5 % of adult CAP [4] . This form of pneumonia was first recognized in the 1930s by Gallagher [5, 6] . The transmission of a filterable 'virus' to the chick embryo amniotic cavity was then reported by Eaton et al. [7] . The Eaton agent, as it was known then, was subsequently recognized as a mycoplasma by Marmion and Goodburn using an intensified Giemsa stain on frozen sections of the chick embryo lung. They detected small coccobacillary bodies in the layer of mucus overlying the cells and arranged in palisade-like fashion on the cell surface [8] . They showed that the organism was sensitive to gold salts (inhibition of infections in hamsters and chick embryos) and that large viruses of the pox group and organisms of the chlamydia group were not sensitive. M. pneumoniae does not respond to the antibiotics that are commonly used to treat typical lobar pneumonia. If appropriate treatment is not instituted early, complications may arise, with multiple extra-pulmonary manifestations [9] .
As there are no pathognomonic or radiological hallmarks that are diagnostic of M. pneumoniae infection, there is a need for rapid laboratory diagnosis [10] . The signs and symptoms of this infection may be similar to those of influenza. However, the laboratory diagnosis of M. pneumoniae has limitations, as the traditional method for culture of the organism requires fastidious and exacting growth conditions, paired sera are needed for serodiagnosis and the high cost of molecular diagnostic methods can be problematic in resource-limited countries. The cold agglutinin test was used in the past to diagnose M. pneumoniae infection as a low-cost approach, but its very low sensitivity and specificity compromised its utility [11] . Therefore, clinically and scientifically validated rapid diagnostic tests are essential for the detection of infectious agents to facilitate prompt and appropriate institution of antibiotics and patient management.
Sri Lanka has a high rate of penicillin resistance in S. pneumoniae, which is the commonest cause for CAP [12, 13] . Penicillin is no longer recommended as empirical therapy for CAP in Sri Lanka and this form of infection is instead treated with broad-spectrum beta-lactams [14] . However, M. pneumoniae infection needs to be treated mainly with either macrolide or quinolones, since the beta-lactams are not effective, as the organism does not possess a cell wall. Therefore, accurate and cost-efficient diagnosis of this infection is needed to focus on appropriate antibiotic prescription and thereby minimize the development of antibiotic resistance.
In Sri Lanka, M. pneumoniae infections are not widely diagnosed or confirmed by laboratory tests and the suspected cases are treated empirically. Empirical therapy should ideally be guided by local prevalence data, including the spectrum of organisms involved and their antibiotic resistance profiles, as well as clinical and laboratory criteria. However, local prevalence data are currently not available for this infection. Having such data would refine the empirical antibiotic guidelines, minimize inappropriate use of broad-spectrum antibiotics and facilitate patient management. This study aimed to determine the detection rate for M. pneumoniae infection in tropical Sri Lanka and to assess cost-effective diagnostics to inform appropriate antibiotic use.
METHODS

Ethical approval
Ethical approval was obtained from the Ethics Review Committee of the Faculty of Medicine, University of Kelaniya, Sri Lanka.
Study setting
This study was conducted prospectively at two tertiary care hospitals in Sri Lanka, namely Colombo North Teaching Hospital, Ragama and the Chest Hospital, Welisara. The two hospitals, 16 km north of the capital, Colombo, are located in the Gampaha district in the Western Province of Sri Lanka.
Study population
Patients with suspected pneumonia, acute bronchitis or acute pharyngitis were included in the study. Pneumonia was diagnosed in patients with clinical or radiological signs and associated features as described by McPhee et al. [15] . Acute bronchitis was diagnosed in those with either a dry or productive cough or retrosternal chest discomfort for not more than 2 weeks. Patients with underlying pulmonary diseases and pneumonia were excluded. Acute pharyngitis was defined as having a sore throat with a history of fever, absence of a cough, enlarged tender tonsils and tender anterior cervical lymphadenopathy. Patients with throat ulcers were excluded from the study. The control group consisted of patients who visited the hospital for illnesses (e.g. diabetes and hypertension) other than respiratory infections. All subjects were more than 12 years of age. The samples were collected during the wet and dry seasons over a period of about 1 year. In Sri Lanka there are four seasons during the year, determined according to rainfall levels. The dry season (December-February) has less than 100 mm of rainfall per month. The first (March and April) and second (October and November) inter-monsoon seasons produce between 100-400 mm rainfall per month. During the wet season (May-September), the rainfall varies from 100 to >3000 mm per month. The required sample size (246) was calculated using the formula: n=Z
2 where n is the sample size, Z is the confidence interval (1.96, 95 %), P is the estimated prevalence (20 %) and d is the margin of error (5 %). Since fewer patients were expected to return with a second blood sample, the study recruited 418 patients (a mix of inpatients and outpatients). The number of patients on antibiotics was not easily ascertained, as the patients were not aware whether antibiotics had been prescribed and widespread use of antibiotics despite regulatory measures was another contributing factor [16] .
Specimens and storage
Three samples were collected per patient: one respiratory sample at the acute stage and two blood samples for paired serology. A sample of peripheral venous blood (3-5 ml) was obtained from each patient under aseptic precautions at the acute and convalescent phases, which were separated by more than 14 days. Sputum samples were obtained from patients with pneumonia or acute bronchitis, while throat swabs were obtained from those with acute pharyngitis and healthy volunteers. Respiratory samples were transported in M. pneumoniae transport media prepared according to Koneman et al. [17] . Respiratory samples were only obtained at the acute stage. The serum and respiratory samples were stored at À20 and À70 C, respectively.
M. pneumoniae IgM, IgG and IgA ELISA tests The enzyme-linked immunosorbent assay (ELISA) used to test for M. pneumoniae-specific antibody isotypes (IgG, IgM or IgA) was purchased from IBL International GmbH, Hamburg, Germany. Briefly, microwell strips were precoated with M. pneumoniae antigen by the manufacturer.
Patients' sera diluted in the manufacturer-supplied diluent buffer (PBS with inert yellow dye) were then added in a volume of 100 µl per well. The reaction was incubated for 1 h at 37 C. After this the wells were washed three times with washing solution, with a soaking time of >5 s between the washing steps. Conjugated anti-human IgG, IgM or IgA was then added to the wells, except for the blank well. This reaction was then incubated for 30 min at 37 C, followed by removal of unbound conjugate with washing as per the procedure described above. Tetramethylbenzidine (TMB) substrate solution was then added in a volume of 100 µl per well and the reaction was incubated at room temperature for 15 min in a light-tight box. The reaction was stopped by the addition of stop solution (100 µl per well) and the absorbance at 450/620 nm was then read with a spectrophotometer (Model ELX800, Bio-Tek Instruments, Inc., USA)
The serological results (positive, negative or equivocal) were interpreted as per the manufacturer's guidelines. The cut-off was the mean absorbance value of the two cut-off control determinations. The cut-off control reagents were provided by the manufacturer. (Example provided by the manufacturer: absorbance value cut-off control 0.39+absorbance value cut-off control 0.37=0.76/2=0.38. Cut-off=0.38). An optical density (OD) reading within ±20 % of the cut-off value was considered to be the grey zone. Samples whose OD values were lower than the lower limit of the grey zone were taken as negative. OD values within the grey zone were considered to be equivocal and OD values above the upper limit of the grey zone were considered to be positive. When an equivocal result occurred in both acute and convalescent samples, the results were interpreted as negative. Patients with positive IgM or IgG seroconversion (!fourfold rise in antibody levels from the acute to the convalescent stage) against M. pneumoniae were considered to be positive.
Interpretation of M. pneumoniae antibody titre (IgM, IgG or IgA) (U ml
À1
)
The OD values for IgM, IgG and IgA were interpreted as positive, negative or equivocal using the following arbitrary units: <8, negative; 8-12, equivocal; and >12, positive. When paired samples showed equivocal values at both times they were taken as negative.
Calculation of IgG antibody titre
The amount of IgG in the sample was calculated using reference IgG concentrations provided by the manufacturer. This was done separately for each IgG test plate. For the calculation of the standard curve, the OD values of the controls (y-axis, linear) were plotted against the concentration (xaxis, logarithmic) of the standards on a semi-logarithmic graph paper. Separate standard curves were drawn for each test plate. Each signal (OD value) of the sample was converted to antibody concentration according to the standard curve of the specific plate. The IgG results were interpreted by comparing the IgG levels in both the acute and the convalescent phase sera.
PCR diagnosis
Preliminary tests showed that the limit of detection with the PCR was 10 copies of M. pneumoniae DNA per sample reaction volume of 50 µl (Fig. 1) . DNA was extracted from the respiratory samples using the Qiaquick DNA kit (Qiagen). DNA extracted from Escherichia coli, S. pneumoniae, Haemophilus influenzae and Pseudomonas aeruginosa yielded negative results in the PCR. Primers were selected to exclusively amplify M. pneumoniae DNA encoding the P1 adherent protein, which is M. pneumoniae's major attachment protein for host respiratory epithelial cells [18] . The possible existence of genetically unrelated organisms that might fortuitously share antigenic cross-reactions with M. pneumoniae was investigated exhaustively. No crossreactions were found with a wide range of common respiratory mycoplasmas, chlamydia and bacteria -including, for example, pneumococci and Streptococcus MG, which share carbohydrate or glycolipid haptens with mycoplasmas [19] . However, there is cross-reactivity with M. genitalium, which not only shares antigens with M. pneumoniae but also has sequence homology (2-8 %) with M. pneumoniae [20] [21] [22] .
The forward primer sequence was (5¢ to 3¢); GCT CAG GTC AAT CTG GCG TG and the reverse primer sequence was (3¢ to 5¢); CAT TCA TCT TTG CGG CGT GT. DNA amplification was carried out in a thermocycler (Autorisierter Thermocycler, Eppendorf Co., Germany) using the following thermal cycling parameters: initial incubation of the sample at 95 C for 10 min, followed by 45 cycles at 95 C for 15 s, annealing at 60 C for 30 s and an extension at 72 C for 30 s. The final extension comprised 72 C for 5 min, with cooling at 4 C. The primer set generated a 190 bp product. The amplified product (5 µl) was separated in 1.5 % agarose gel and stained with SybrGreen (1 µg ml
À1
). The specific amplified band was identified by comparison with a standard DNA MW marker ladder (50 bp) (Fig. 2) .
Patient demographics and clinical categories
The demographic and clinical data for patients were recorded using an interview-administered questionnaire and clinical data were abstracted from bed head records. The data were analysed using Epi Info 6, version 6.04d (Center for Disease Control and Prevention, Atlanta, Ga, The mean ages of the patients with respiratory illness and the healthy controls were 35.3±17.0 and 42.3±15.3 years, respectively. The male : female ratios for patients with respiratory tract illness and the control group were 55 : 46 and 66 : 35, respectively. The mean duration of illness at acute sampling was highest for patients with pneumonia (17 days) and lowest for patients with acute pharyngitis (3 days) ( Table 1 ). The study group comprised 418 patients, with 97 
RESULTS
Serology
A total of 418 paired sera were tested for IgM, IgG and IgA responses against M. pneumoniae in patients with respiratory illness. The predominant antibody class identified was IgG, followed by IgM and IgA (Table 2 ). It was found that 1.9 % (8/418), 6.5 % (27/418) and 1 % (4/418) of patients were positive for IgM, IgG and IgA antibodies, respectively. Further, 37.5 % (3/8) and 12.5 % (1/8) of IgM-positive patients were also positive for IgG and IgA, respectively. In the group of 27 IgG-positive patients, 11.1 % (3/27) and 14.8 % (4/27) showed IgM and IgA responses, respectively. M. pneumoniae-specific IgA was only detected in patients who were IgG-(4/4) or IgM-positive (1/4), but not alone. One patient with pneumonia (Fig. 3) .
The serological diagnosis of M. pneumoniae infection was made by either positive IgM or IgG response or both, as testing for IgM and IgG antibodies in paired sera has been identified as essential for the diagnosis of recent or current M. pneumoniae infection, especially in adults [23] . (Table 3) . Within the pneumonia group, 77.8 % (7/9) were PCR-positive and within the bronchitis group, 50 % (6/12) were. None of the serologically confirmed cases of pharyngitis were positive for M. pneumoniae DNA. In the control group, two patients were IgM-positive but DNA-negative (Tables 4 and 5 ).
M. pneumoniae DNA detection in seronegative patients
Amongst the 26 patients who were antibody-negative for M. pneumoniae, 15.4 % (4/26) were positive for M. pneumoniae DNA by PCR (Table 4) . Two patients with pneumonia 
Pharyngitis (n=5) (Table 5) .
Antibody class response and DNA detection in relation to duration of symptoms Fig. 4 shows the three classes of M. pneumoniae-specific antibodies and DNA detected in relation to the period of illness in patients with pneumonia or acute bronchitis. All eight IgMpositive patients (six with pneumonia and two with bronchitis) were detected during the first 6 weeks of illness. IgG response was detected in 78.3 % (18/23) during the first month of illness, with the remaining 21.7 % (5/23) extending from 1 to more than 3 months. In the latter group of IgG positives, four of the patients showed no IgM or IgA responses in this period and cough was the most pronounced feature amongst them. Although only three patients mounted IgA responses, these occurred during the first 3 weeks of illness. Almost all [92.3 % (12/13)] of the DNA positives were clustered within the first 2 weeks of illness.
DISCUSSION
Serology plays a major role in the diagnosis of most infections, including M. pneumoniae [24, 25] . In this study, the seroprevalence of M. pneumoniae infection was 17.5 % (17/ 97), 7.1 % (13/183) and 1.4 % (2/138) in patients with pneumonia, bronchitis and pharyngitis, respectively. To the best of our knowledge, this is the first study in Sri Lanka involving patient groups with defined respiratory illness (i.e. pneumonia, acute bronchitis and acute pharyngitis) being tested for class-specific antibody responses (i.e. IgM, IgG and IgA) in paired sera, together with molecular diagnosis in a large cohort of patients (418) over a period of 1 year.
In the group with pneumonia, the findings were similar to those for the excellent long-term studies conducted from 1964-1975 by the Group Health Cooperative, Seattle, USA which found that 15-20 % of all pneumonia was associated with M. pneumoniae [26] . The incidence of M. pneumoniae infection was 17.5 % (17/97) in patients with pneumonia in this study, as determined by serodiagnosis.
M. pneumoniae-specific IgG was, as expected, the most prominent antibody response, with response levels of 14.4 % (14/97), 6.0 % (11/183) and 1.4 % (2/138) in patients with pneumonia, bronchitis and pharyngitis, respectively (Table 2) . Accordingly, amongst the seropositive patients, IgG was the most prominent antibody detected (27/32, 84.4 %). The predominant IgG response observed in this study is comparable to that for a group of adult patients with atypical pneumonia [27] . IgM testing produced positive results in 8 out of 32 seropositive patients (25.0 %). Studies by Chang et al. in 2014 showed that M. pneumoniae IgM has low sensitivity and positive predictive value [28] . This may be due to the possibility of a prominent secondary IgG response being mounted in adults who might have repeat infections, with minimal or undetectable IgM response. Therefore, in a resource-limited country, it is economical to test for IgG rather than both IgG and IgM, particularly in adult patients suspected to have M. pneumoniae infections, since the majority (84.4 %) would be diagnosed by testing for M. pneumoniae-specific IgG. In the seropositive group using paired sera, it is noted that IgM alone would detect one-quarter (8/32, 25.0 %) of patients, while IgG alone would detect more than four-fifths (4/5) of patients with M. pneumoniae infections (27/32, 84.4 %).
M. pneumoniae-specific IgA was only detected in patients with pneumonia, making it more specific for the diagnosis of M. pneumoniae pneumonia. However, the detection rate was low, at approximately 1 % (4/418). It is noted that IgA was not detected in seropositive groups of patients with bronchitis or pharyngitis or controls ( In this study, 77.8 % (7/9) ( Table 5 ) of pneumonia patients who were seropositive for M. pneumoniae infection were PCR-positive, which would give early diagnosis compared to paired serological interpretation with IgG response. M. pneumoniae DNA was detected in 50 % of seropositive patients with bronchitis. As expected, this study showed that PCR is a sensitive test to identify the majority of patients with M. pneumoniae pneumonia, and to a lesser extent those with bronchitis, while it has limited or no value for those with pharyngitis. However, it is noted that PCR alone would miss approximately 20 % of pneumonia patients who are seropositive. Of the PCR negatives in the seropositive group, 81.8 % (9/11) were IgG-positive and the remaining 18.2 % (2/11) were IgM-positive (Table 2) . Therefore, if the PCR was negative, then testing for the serological response (particularly IgG) would be beneficial. In seronegative patients, M. pneumoniae DNA was detected in 16.7 % (2/12) of patients with pneumonia and 22.2 % of patients with acute bronchitis, while it was not detected in any patients with acute pharyngitis (Table 2 ). This indicates that the organism was present in the respiratory tract of seronegative patients. Serological tests alone would miss this cohort of patients. This is in accordance with the study by Nilsson, Bjorkman and Persson, which reported that PCR is superior to serology, especially during the early phase of infection [32] . During the early stage of illness, the patient would be expected to require a lag period to show a detectable level of antibodies. Interestingly, as in seropositive patients, the M. pneumoniae DNA detection rate decreased for those with decreasing severity of respiratory symptoms [pneumonia (70 %, 7/10), bronchitis (50 %, 6/12) and pharyngitis (0 %, 0/3)].
Due to the need for timely diagnosis and management of patients, positive serology and PCR data were compared against the duration of illness and it was found that IgM and DNA need to be tested during the first 2 weeks of illness (Fig. 4) . IgG was observed to be prominent after 2 weeks of illness, but is sustained for a longer period. Therefore, to demonstrate a fourfold rise, acute sample testing for IgG should be performed at the very early stage of the illness. The findings of this 1-year study with more than 400 patients will better inform prompt management of patients with respiratory illness, and pneumonia in particular. Importantly, this will facilitate the judicious use of antibiotics and minimize the development of antibiotic resistance.
In conclusion, the seroprevalence of M. pneumoniae infection in Sri Lanka was 17. 
